{"id":"methotrexate-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-15%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in the inhibition of rapidly dividing cells, such as cancer cells and activated immune cells. Methotrexate also has immunosuppressive properties, making it useful for treating autoimmune diseases.","oneSentence":"Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:58.414Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT03103334","phase":"PHASE1","title":"A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.","status":"COMPLETED","sponsor":"Crossject","startDate":"2014-06","conditions":"Healthy","enrollment":58},{"nctId":"NCT03172325","phase":"PHASE3","title":"Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2015-11-18","conditions":"Active Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT02065713","phase":"PHASE3","title":"Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Instituto de Medicina Molecular João Lobo Antunes","startDate":"2014-08","conditions":"Psoriatic Arthritis","enrollment":44},{"nctId":"NCT02319642","phase":"PHASE3","title":"An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2014-11","conditions":"Rheumatoid Arthritis","enrollment":347},{"nctId":"NCT01521923","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":359},{"nctId":"NCT01519791","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":880},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT02151851","phase":"PHASE3","title":"A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma SA, Belgium","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":430},{"nctId":"NCT01676701","phase":"PHASE3","title":"Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT03403140","phase":"PHASE3","title":"Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2016-10-06","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT03332719","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Gema Biotech S.A.","startDate":"2016-02","conditions":"Rheumatoid Arthritis","enrollment":168},{"nctId":"NCT01443364","phase":"PHASE4","title":"Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Italy s.p.a.","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT02057250","phase":"PHASE3","title":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"RA","enrollment":217},{"nctId":"NCT01900431","phase":"PHASE2","title":"Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-10","conditions":"Uveitis","enrollment":58},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT01844895","phase":"PHASE3","title":"Methotrexate-Inadequate Response Autoinjector Device Sub Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT01793259","phase":"PHASE3","title":"Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"methotrexate prefilled syringe","genericName":"methotrexate prefilled syringe","companyName":"medac GmbH","companyId":"medac-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate is a small molecule used in the treatment of conditions such as rheumatoid arthritis. It is administered via a prefilled syringe.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}